Loading
Latest filing published 27 May 2026 for Co-Diagnostics, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Richard S. Serbin, listed as board member, appears in our data through filings on Co-Diagnostics, Inc. shares, published by SEC (Form 4). In total, 10 filings cover trades dated from 8 January 2022 to 23 May 2026.
The filings describe grants, exercises and other transfers rather than trades on the open market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
Most recently, on 27 May 2026, the filings show a share grant in Co-Diagnostics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
10 of 10 declarations